11-15-2023: Beijing, China: "Among lung cancer patients, immune checkpoint inhibitor pneumonitis is a life-threatening, adverse event" https://t.co/0lJtWlOiBm https://t.co/QCK55Lot5t https://t.co/45vIuyIbNI https://t.co/WcTLv5irUJ https://t.co/3T8UD6Uf4S
10-2023: Takeda has failed their terminal lung cancer drug, Exkivity (mobocertinib): https://t.co/DaBi3UCPni https://t.co/0lJtWlOiBm https://t.co/QCK55Lot5t https://t.co/3T8UD6Uf4S https://t.co/WcTLv5irUJ https://t.co/45vIuyIbNI https://t.co/2gRtB5cLVv ht
10-11-2022: China: The anti-cancer drug, Actemra (tocilizumab), targeted the cancer-associated fibroblasts in metastatic lung cancer: https://t.co/DaBi3UCPni https://t.co/0lJtWlOiBm https://t.co/QCK55Lot5t https://t.co/45vIuyIbNI https://t.co/WcTLv5irUJ h
1-11-2022: Beijing, China: IL-6 blocker vs. PD-L1 blocker vs. paclitaxel for treating metastatic lung cancer: https://t.co/5cldUzfKIN https://t.co/DaBi3UkG9a https://t.co/0lJtWm5lDm https://t.co/QCK55LFw7t https://t.co/45vIuyZePI https://t.co/1t2gOOcKCB